UCB's new meds spur sales growth; Otsuka nabs NICE backing for kidney med;

> Belgium's UCB hiked its full-year financial outlook on strong growth of three of its new drugs--Cimzia, Vimpat and Neupro--and ongoing sales of its off-patent epilepsy med Keppra. Report

> Otsuka's Jinarc, a treatment for autosomal dominant polycystic kidney disease, won backing from England's cost-effectiveness watchdogs. Report

> Merck & Co. ($MRK) said its price cut on Remicade in the U.K. will save England's National Health Service millions of pounds. Report

And Finally... More than three-fourths of Americans say the cost of prescription drugs for serious diseases is their chief health concern, a Kaiser Family Foundation poll found. Report

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.